NCT06492915 - Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

July 1, 2026

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

Chiauranib

Chiauranib, 25 mg, 35 mg or 50 mg, oral administration once daily

DRUG

Albumin-paclitaxel Injection

Albumin-paclitaxel Injection, 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle

DRUG

Gemcitabine Injection

Gemcitabine Injection, 1000 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai